Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), today announced its largest portfolio expansion in Australia ...

(Anastassiya Bezhekeneva/Getty Images) A large umbrella review has found no strong evidence to date that medicinal cannabis ...

By Sriparna Roy March 16 (Reuters) - Cannabis-based medicines have shown little evidence of effectiveness for treating most ...

EDMONTON, AB, June 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the ...

Increasing numbers of Australians are using medicinal cannabis for anxiety, depression, insomnia, substance disorders and ...

There’s “no evidence” that medical marijuana is effective in treating anxiety, depression or post-traumatic stress, according ...

The largest systematic review, published in The Lancet Psychiatry, finds medical cannabis does not benefit anxiety, depression, or PTSD and highlights risks, questioning current prescriptions A major ...

A new analysis represents the largest effort yet to systematically parse all the data from high-quality clinical trials on cannabis and mental health. The evidence is lacking.

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a global leader in medical cannabis, empowering the ...

Employees sacked by Australia’s biggest medicinal cannabis company say its medical affairs team has been gutted, raising ...

Years in the making, the Canadian LP is finding markets closer to the pharmaceutical industry in highly regulated medical cannabis markets.

Chief Financial Officer Simona King outlined the company’s recent strategic pivot toward medical cannabis and international expansion during a fireside chat at the TD Cowen Healthcare Conference, ...